Newsroom

July 18, 2024 Seer to Report Second Quarter 2024 Financial Results on August 8, 2024 June 11, 2024 Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery June 2, 2024 Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study May 8, 2024 Seer Reports First Quarter 2024 Financial Results May 8, 2024 Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions April 23, 2024 Seer to Report First Quarter 2024 Financial Results on May 8, 2024 February 29, 2024 Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook February 21, 2024 Seer to Participate in the TD Cowen 44th Annual Health Care Conference February 6, 2024 Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery February 1, 2024 Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 December 21, 2023 Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference November 10, 2023 Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum November 8, 2023 Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500 November 7, 2023 Seer Reports Third Quarter 2023 Financial Results November 1, 2023 Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program October 19, 2023 Seer to Report Third Quarter 2023 Financial Results on November 7, 2023 September 8, 2023 Seer to Participate in Upcoming September Investor Conferences August 8, 2023 Seer Reports Second Quarter 2023 Financial Results July 27, 2023 Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference July 13, 2023 Seer to Report Second Quarter 2023 Financial Results on August 8, 2023 June 7, 2023 Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center June 1, 2023 Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies May 9, 2023 Seer Reports First Quarter 2023 Financial Results April 20, 2023 Seer to Report First Quarter 2023 Financial Results on May 9, 2023 March 29, 2023 Seer’s Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression March 2, 2023 Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook February 21, 2023 Seer to Present at the Cowen 43rd Annual Health Care Conference February 9, 2023 Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023 December 27, 2022 Seer to Present at the J.P. Morgan 41st Annual Health Care Conference December 12, 2022 Seer’s Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist November 8, 2022 Seer Reports Third Quarter 2022 Financial Results October 13, 2022 Seer to Report Third Quarter 2022 Financial Results on November 8, 2022 August 30, 2022 Seer to Participate in the Morgan Stanley Global Healthcare Conference August 23, 2022 Seer Announces Publication of Seminal Study Demonstrating the Power of Engineered Nano-Bio Interactions to Enable Deep Access to the Proteome August 9, 2022 Seer Reports Second Quarter 2022 Financial Results August 3, 2022 Seer Launches First-of-its-kind Proteogenomics Workflow to Link Genetic Changes with Protein Variants with Proteograph™ Analysis Suite 2.0 July 14, 2022 Seer to Report Second Quarter 2022 Financial Results on August 9, 2022 May 4, 2022 Seer Reports First Quarter 2022 Financial Results April 28, 2022 Seer to Present at the BofA Securities 2022 Healthcare Conference April 7, 2022 Seer to Report First Quarter Financial Results on May 4, 2022 March 16, 2022 Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer March 14, 2022 Seer Announces Publication of Seminal Study Demonstrating Superior Performance of Technology Platform for Deep, Unbiased, Precise, Scalable Proteomics in the Proceedings of the National Academy of Sciences February 28, 2022 Seer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook February 22, 2022 Seer to Present at the Cowen 42nd Annual Health Care Conference February 1, 2022 Seer to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022 January 10, 2022 Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program January 10, 2022 Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies December 29, 2021 Seer to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference November 29, 2021 Seer Appoints Meeta Gulyani to its Board of Directors November 22, 2021 Seer to Participate in the Piper Sandler Virtual Healthcare Conference November 9, 2021 Seer Reports Third Quarter 2021 Financial Results November 8, 2021 Seer Appoints Rachel Haurwitz, Ph.D., to its Board of Directors October 12, 2021 Seer to Report Third Quarter Financial Results on November 9, 2021 September 2, 2021 Seer to Present at the Morgan Stanley Global Healthcare Conference August 12, 2021 Seer Reports Second Quarter 2021 Financial Results August 12, 2021 Seer Bio Partners with Enlight Medical to Commercialize the Proteograph™ Product Suite in China July 13, 2021 Seer to Report Second Quarter Financial Results on August 12, 2021 May 10, 2021 Seer Reports First Quarter 2021 Financial Results May 4, 2021 Seer to Present at the BofA Securities 2021 Healthcare Conference April 12, 2021 Seer to Report First Quarter Financial Results on May 10, 2021 March 29, 2021 Seer Reports Fourth Quarter and Full Year 2020 Financial Results and Fuels Commercial Progress in 2021 with New Collaborators and Partnerships March 29, 2021 Seer and SCIEX Sign Commercial Agreement to Offer End-to-End Unbiased Proteomics Solutions March 1, 2021 Seer to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021 February 24, 2021 Seer to Present at the Cowen 41st Annual Healthcare Conference February 17, 2021 Seer Appoints Deep Nishar and Mostafa Ronaghi, Ph.D. to its Board of Directors February 1, 2021 Seer Announces Closing of Public Offering of Common Stock January 27, 2021 Seer Announces Pricing of Upsized Public Offering of Common Stock January 25, 2021 Seer Announces Proposed Public Offering of Common Stock January 11, 2021 Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics January 11, 2021 Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics January 4, 2021 Seer to Present at the 39th Annual J.P. Morgan Healthcare Conference December 8, 2020 Seer Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares December 3, 2020 Seer Announces Pricing of Initial Public Offering September 15, 2020 Seer Appoints Catherine Friedman to its Board of Directors September 15, 2020 Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing July 22, 2020 Seer Announces $55M Financing Led by Fidelity Management and Research Company July 22, 2020 Seers Announces Publication in Nature Communications Demonstrating Performance, Scalability and Utility of its Platform Technology for Deep, Unbiased Proteomics May 19, 2020 Seer Announces Appointment of David R. Horn as Chief Financial Officer May 12, 2020 Seer Announces Appointment of Omead Ostadan as President and Chief Operating Officer December 17, 2019 Seer Announces $55 Million in Series D Equity Financing July 18, 2019 Seer Announces Appointment of Mark McClellan, MD, PhD to Board of Directors